According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- top-line data of the Phase 1 Clinical Trial indicated that DSG3-CAART had, among other things, worsened certain participants’ disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion;
- accordingly, DSG3-CAART was not as effective as the Company had represented to investors;
- therefore, the Company had overstated DSG3-CAART’s clinical and/or commercial prospects; and
- as a result, the Company’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.